Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

Seven Fleet Capital Management LP raised its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 140.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,504,400 shares of the company’s stock after purchasing an additional 878,692 shares during the period. Taysha Gene Therapies makes up approximately 1.6% of Seven Fleet Capital Management LP’s holdings, making the stock its 13th biggest position. Seven Fleet Capital Management LP owned 0.46% of Taysha Gene Therapies worth $9,940,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. AQR Capital Management LLC raised its position in shares of Taysha Gene Therapies by 325.6% during the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after buying an additional 82,545 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Taysha Gene Therapies by 13.5% in the second quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock valued at $539,000 after buying an additional 27,794 shares during the period. Prudential Financial Inc. grew its position in Taysha Gene Therapies by 50.5% during the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock worth $53,000 after buying an additional 7,650 shares in the last quarter. Invesco Ltd. grew its position in Taysha Gene Therapies by 27.4% during the second quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock worth $470,000 after buying an additional 43,772 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Taysha Gene Therapies during the second quarter valued at about $184,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TSHA. The Goldman Sachs Group raised their price objective on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. BMO Capital Markets boosted their price objective on Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, June 23rd. Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a research note on Tuesday, June 23rd. Robert W. Baird lifted their price target on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $11.00 price target on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.77.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the completion of the transaction, the insider owned 936,410 shares in the company, valued at $5,843,198.40. The trade was a 17.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by corporate insiders.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ:TSHA opened at $5.60 on Friday. The business has a fifty day moving average of $6.06 and a 200-day moving average of $5.63. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.76 and a current ratio of 17.76. Taysha Gene Therapies, Inc. has a twelve month low of $2.71 and a twelve month high of $7.30. The firm has a market cap of $1.82 billion, a PE ratio of -13.33 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities research analysts predict that Taysha Gene Therapies, Inc. will post -0.52 EPS for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.